Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for pulsatile tinnitus of vascular origin. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). Pulsatile tinnitus is a symptom requiring imaging workup, not a primary diagnosis. Only a handful of case reports describe leech therapy in this setting. Evidence-based first-line management is identifying and treating the underlying cause (dural arteriovenous fistula, sigmoid sinus diverticulum, carotid stenosis, idiopathic intracranial hypertension) via MRA/CTA and neurosurgical, interventional radiology, or ENT-directed therapy.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Who should not consider this
- Patients who have not had imaging workup (MRA/MRV/CTA) — a treatable vascular lesion may be missed
- Patients with a known carotid dissection, carotid stenosis, dural AV fistula, or intracranial aneurysm
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- What to ask your clinician
- Have I had MRA, MRV, or CTA to look for a treatable cause of the pulsing sound?
- Has an ENT or neurosurgeon ruled out structural problems like a sigmoid sinus diverticulum?
- If a cause is found, would catheter-based or surgical treatment cure the tinnitus completely?
- What is the expected response rate and how would success be measured?
- Could the leech therapy mask worsening of a serious vascular cause?
- What are non-invasive options like sound therapy or CBT for tinnitus distress?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden hearing loss, severe headache, facial weakness, slurred speech, or vision changes
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for pulsatile tinnitus — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace imaging workup — pulsatile tinnitus can be the first sign of treatable vascular pathology that requires endovascular or surgical repair.
- It does not have RCT or even consistent case-series evidence supporting efficacy.
- It does not address most causes of pulsatile tinnitus, which are anatomic rather than inflammatory.
- It does not work for non-pulsatile (continuous) tinnitus, which has a different physiology.
Safety cross-references
Clinical Profile
- Category
- ent
- ICD-10
- H93.A1, H93.A2, H93.A3, H93.A9
- Safety tier
- medium
Evidence Summary
Pulsatile tinnitus has an identifiable vascular substrate in the majority of cases (sigmoid sinus diverticulum, idiopathic intracranial hypertension, atherosclerotic carotid disease). No controlled clinical trial of leech therapy for pulsatile tinnitus exists; any use is investigational and anecdotal only. Structural causes must be excluded by MR venography or CT angiography before any complementary intervention is even considered. Hirudotherapy is not a substitute for definitive vascular treatment when an anatomic lesion is identified.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Khan IA et al. (2019), n=12
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- Untreated structural vascular lesion (dural fistula, sinus stenosis, carotid stenosis)
- Active middle ear infection
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Meniere's Disease (Vestibular Attack Frequency)
Investigational adjunct for vestibular attack frequency reduction in definite Meniere's disease per AAO-HNS 2015 criteria; case-series evidence.